Respiratory Quiz - Module 9

There is no need for patients to avoid eating food at the same time as administering montelukast. This means that it is not necessary to separate the intake of food and montelukast.

(true), especially in children below the age of 5

The statement suggests that Montelukast has many severe side effects. However, the correct answer is False, which means that Montelukast does not have many severe side effects. This implies that the statement is incorrect and Montelukast is not associated with severe side effects.

The lipoxygenase pathway is a metabolic pathway involved in the production of leukotrienes, which are inflammatory mediators. Leukotriene modifiers are drugs that can interfere with this pathway by inhibiting the activity of lipoxygenase enzymes or blocking the receptors for leukotrienes. Therefore, it is true that the lipoxygenase pathway can be interfered with by leukotriene modifiers.

(false) 4 mg for ages 6 months to 5, 5 mg for 6 to 14, and 10 mg for > 15 years.

(false) They cause allergic inflammation.

(false) they can be used to treat diseases with allergic inflammation

Leukotriene receptor antagonists are not indicated for monotherapy for severe persistent asthma. They are usually used as an add-on therapy to inhaled corticosteroids for the management of asthma symptoms. Monotherapy with leukotriene receptor antagonists may be considered for mild persistent asthma, but for severe persistent asthma, a combination of medications is typically required to achieve optimal control of symptoms.

(false) It is a FLAP inhibitor. Montelukast, zafirlukast and pranlukast are receptor antagonists.

(false) Singulair is the originator of montelukast and Accolate is the originator zafirlukast